Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

India’s latest cancer drug price revision has reduced the maximum retail prices (MRPs) of several anti-cancer medicines. While the average price reduction comes around to be more than 50%, roughly one in four of the listed drugs still remain unchanged.

Also, the overall decline across all products is only 13.8%, according to an analysis by the Working Group on Access to Medicines and Treatments.

The analysis examined 643 anti-cancer drugs that were a part of the revised price list issued by the National Pharmaceutical Pricing Authority (NPPA). 484 products, or 75.27%, recorded a price reduction, while 159 products, accounting for 24.73%, remained unchanged.

Why Is Overall Price Reduction In Cancer Drugs Only 13.8%?

Also read: Top Neurologist Says Stroke Could Be First Sign of Undiagnosed Cancer: Red Flags to Know | Interview

Among products that became cheaper, the average price reduction was 50.78%. But when the combined listed MRPs of all 643 products were compared, the overall reduction was only 13.8%.

The difference between the two figures reflects the fact that many expensive cancer medicines have remained unaffected.

According to the working group’s analysis, the combined listed MRP of all 643 products fell from approximately ₹2.51 crore to ₹2.17 crore, marking a reduction of around ₹34.57 lakh.

However, the 159 products that recorded no price reduction accounted for 86.2% of the combined revised MRP value of the entire list.

“Of course, average can be misleading,” said KM Gopakumar, researcher with the Third World Network and co-convenor of the working group. “This weighted reduction gives us much more a realistic view.”

Expensive Cancer Drugs Remain Unchanged

Also read: Cancer Drug Prices Slashed For 543 Brands From Nov 9, But A Blockbuster Drug That Treats 21 Cancers Remains Untouched

The analysis found that several expensive cancer drug brands, including medicines manufactured by multinational pharmaceutical companies, retained their earlier MRPs. These include:

• Keytruda (pembrolizumab): The listed price remains ₹2,16,500 for a 100 mg injection.
• Tagrisso (osimertinib): The price remains approximately ₹4.16 lakh for a pack of 30 tablets.
• Avastin (bevacizumab): Roche’s 400 mg vial remains priced at ₹1,23,506.
• Alimta (pemetrexed): Eli Lilly’s 500 mg injection remains priced at ₹29,531.25.

The analysis also found that 110 of 122 products examined across 18 selected multinational pharmaceutical companies recorded no price reduction. Their average price reduction across all 122 products was just 1.3%.

On the other hand, several generic medicines recorded substantial cuts. For example, the price of a 400 mg bevacizumab vial sold as Bevacirel by Reliance Life Sciences fell by 83.27%, while Abbott Healthcare’s Bevacizab recorded an 86.26% reduction.

Call For Further Action

The Working Group on Access to Medicines and Treatments has urged the government to consider additional measures to improve access to expensive cancer medicines.

It has called for public health safeguards under Sections 92 and 100 of the Patents Act, which provide for compulsory licensing and government use of patented inventions in particular circumstances.

Such provisions can allow access to patented medicines under defined legal conditions when public health requirements warrant intervention.

The group has also questioned the trade margin framework, arguing that the margins remain high and that the government should disclose the calculations used to ascertain revised MRPs.

The NPPA introduced the latest intervention to address excessive trade margins and reduce the cost of cancer medicines.

Its October 28 list initially covered 543 brands, with subsequent updates expanding the coverage to 643 products.

The price revisions suggest that the overall impact remains limited because pricey drugs have not become cheaper. So patients who need expensive patented treatments, the latest price cuts may therefore offer little direct relief.

Barbados recently joined the list of 26 countries and territories that have been certified by the World Health Organization for eliminating mother-to-child-transmission (EMTCT) of HIV, syphilis or hepatitis B. 15 of these countries are in the Americas, which makes the region a global leader to achieve this feat.

The major public health milestone comes after years of sustained efforts to prevent mother-to-child-transmission of HIV.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said, “I congratulate Barbados on protecting a generation of children from HIV,” said “Barbados has shown what universal health coverage looks like in practice: free services for every pregnant woman, regardless of nationality, and care that respects her rights and privacy. With 15 countries and territories in the Americas now recognized, the region continues to show the world the way.”

How Did Barbados Prevent Mother-To-Child HIV Transmission?

Also read: Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It

The Caribbean country's achievement was backed by widespread coverage of antenatal care, HIV testing and antiretroviral treatment.

“Barbados has shown that eliminating mother-to-child transmission of HIV is possible when women and children have access to quality health services without barriers,” said Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO) and WHO Regional Director for the Americas.

“This achievement means that children are born free of HIV and that women living with HIV can access the care and treatment they need. It is a proud moment for Barbados, the Caribbean, and the global effort to end AIDS in children.”

During the three-year period, 98% of pregnant women received antenatal care, 98% were tested for HIV, and 98% of pregnant women living with HIV received antiretroviral treatment.

An essential step in Barbados' HIV elimination strategy is making HIV testing and treatment accessible to all pregnant women. Free HIV testing and treatment are available to all pregnant women regardless of race and nationality. These services are available through public clinics and hospitals.

“This is incredible for us, and it allows us to be able to see our children living their full, best lives. It allows mothers to be able to have the benefit of treatment during pregnancy, before treatment, but also, it means that we're able to ensure that we have a healthier population, and we're able to join the other countries around the globe that have also equally been able to achieve this historic milestone,” said Lisa Cummins, Minister of Health and Wellness of Barbados.

Additionally, pregnant women are offered voluntary and confidential HIV testing. Those who test positive are provided specialised care and treatment to reduce the risk of passing the virus to their babies.

Antiretroviral therapy (ART) is central to preventing mother-to-child HIV transmission. These medicines suppress HIV in the body, reducing the amount of virus in the blood. When an HIV+ pregnant woman receives ART, the risk of transmission to her baby can be reduced significantly.

Barbados also provides early testing and follow-up care for babies at risk of contracting HIV from their mothers.

Also read: 1 In 60 Adults In Fiji May Now Have HIV As Meth Use, Unsafe Injecting And Treatment Gaps Fuel Surge

How Does HIV Pass From Mother To Child?

HIV can be transmitted from a woman living with HIV to her child during pregnancy, childbirth or breastfeeding. This is known as vertical transmission or mother-to-child transmission.

Without preventive interventions, the risk of transmission can be significant. However, timely diagnosis, antiretroviral treatment during pregnancy and appropriate care around childbirth can substantially reduce this risk.

With effective treatment and appropriate medical support, women living with HIV can have children who are born without the infection.

The WHO certification recognises that Barbados has brought transmission down to a level at which it is no longer considered a public health problem. It does not mean that HIV has been eliminated from the country.

In a world first, scientists have administered AI-designed viruses to a human patient to treat a serious antibiotic-resistant bacterial infection. The experimental treatment marks a milestone in the development of personalized therapies that use artificial intelligence (AI) to design viruses capable of targeting drug-resistant bacteria.

California-based AI startup Radical Numerics announced the development in a blog post, saying a patient with a serious bacterial infection received an experimental treatment containing viruses generated by its AI model, Omnii-1.

How AI Helped Design the Viruses

Also read: AI Creates 16 Viruses To Kill Drug-Resistant E. coli, Raises Biosafety Concerns

The treatment uses bacteriophages, or phages, which are viruses that infect and kill bacteria. Phage therapy is being explored as an alternative when antibiotics fail, particularly in drug-resistant infections.

However, identifying phages that can effectively target the specific bacteria causing an individual patient's infection remains a major challenge.

Antibiotic resistance is a growing global health threat. A 2024 study published in The Lancet projected that bacterial antimicrobial resistance could directly cause 39.1 million deaths globally between 2025 and 2050.

Radical Numerics said it trained Omnii-1, its multimodal genome language model, to address the challenge of identifying and designing effective phages.

"We trained Omnii-1, our multimodal genome language model, to help bridge this gap. We demonstrate that it can generate viable phages, prioritize variants, and predict phage-host interactions," the company said.

"In the world's first clinical use of AI-generated phages, Omnii-1 designs were administered to a human patient under compassionate use," it added.

How Did the AI-Designed Phage Treatment Work?

Read More: Anthropic Says Claude Blocked Bird Flu, Chikungunya Research: How AI Could Enable Biological Misuse

According to the company, researchers tested the AI-designed viruses against bacteria obtained from the patient before administering the treatment. The resulting phage cocktail eliminated the patient's antibiotic-resistant bacterial sample in laboratory testing.

The treatment was administered under an authorized, physician-led compassionate-use pathway. Compassionate use allows patients with serious conditions to access investigational treatments outside clinical trials when satisfactory alternatives are unavailable, subject to regulatory authorization and appropriate oversight.

The report has not been peer-reviewed or published in a scientific journal. Company officials said the trial had been authorized by the Food and Drug Administration, the New York Times reported.

The company has not disclosed the patient's diagnosis, clinical course or treatment outcome, citing privacy concerns. It is therefore unclear whether the treatment successfully cleared the infection.

Eric Nguyen, chief executive officer of Radical Numerics, said the company was prioritizing patient confidentiality and intended to publish its findings through peer-reviewed research.

"We intend to publish our scientific findings through peer-reviewed research, with any future disclosure of clinical details subject to appropriate consent," he added.

The company said making phage therapy accessible to more patients would require reliable workflows for designing effective phages against individual bacterial infections.

Previous Research Used AI to Design Bacteria-Killing Viruses

The development comes amid growing interest in using AI to accelerate medical research, including the design of new biological therapies.

In August 2026, researchers at Stanford University and the Arc Institute announced that they had used AI to design previously unseen bacteriophages capable of killing E. coli bacteria in laboratory experiments.

Of nearly 300 AI-designed phages synthesized and tested, 16 produced functional viruses. However, these experiments were conducted in bacteria and did not involve human patients.

The Radical Numerics development goes a step further by reporting the clinical administration of AI-designed phages to a human patient.